New immune cell therapy trial targets Tough-to-Treat lymphoma
NCT ID NCT07125872
Summary
This study is testing a new combination of three drugs for adults whose B-cell non-Hodgkin lymphoma has come back or stopped responding to standard treatments. The treatment involves a short course of chemotherapy followed by infusions of engineered immune cells (CD19 t-haNK), an immune-boosting drug (N-803), and an antibody therapy (rituximab). The main goals are to see if this combination can shrink the cancer and extend survival, while closely monitoring side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED B-CELL NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Albert Cellular Therapy
RECRUITINGPretoria, 0044, South Africa
Contact
Contact Email: •••••@•••••
Contact Email: •••••@•••••
-
Dr. Jackie Thomson Inc
RECRUITINGJohannesburg, 2193, South Africa
Contact
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.